Short Interest in BiomX Inc. (NYSEAMERICAN:PHGE) Drops By 92.9%

BiomX Inc. (NYSEAMERICAN:PHGE) saw a significant decline in short interest in August. As of August 15th, there was short interest totalling 58,100 shares, a decline of 92.9% from the July 31st total of 812,700 shares. Based on an average daily trading volume, of 30,100 shares, the short-interest ratio is currently 1.9 days.

Institutional Trading of BiomX

A hedge fund recently bought a new stake in BiomX stock. 8VC GP I LLC bought a new stake in shares of BiomX Inc. (NYSEAMERICAN:PHGE) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,086,191 shares of the company’s stock, valued at approximately $304,000. BiomX accounts for 0.3% of 8VC GP I LLC’s holdings, making the stock its 3rd largest holding. 8VC GP I LLC owned about 2.36% of BiomX at the end of the most recent reporting period. Institutional investors and hedge funds own 40.57% of the company’s stock.

BiomX Stock Performance

Shares of NYSEAMERICAN:PHGE traded down $0.14 on Thursday, reaching $1.26. The company’s stock had a trading volume of 231,627 shares, compared to its average volume of 120,637. BiomX has a 52-week low of $1.15 and a 52-week high of $8.55. The company has a quick ratio of 4.40, a current ratio of 4.40 and a debt-to-equity ratio of 1.75. The stock has a market capitalization of $87.96 million, a P/E ratio of -2.07 and a beta of 1.32.

About BiomX

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).